Tag: Fexapotide Triflutate

April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 1, 2018

5 Top NASDAQ Biotech Stocks: Cardiome on Top

Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices.
March 18, 2018

5 Top NASDAQ Biotech Stocks: Second Sight Medical on Top

Second Sight, Juniper, Athersys, Aptose and ArQule were last week's five top-gaining NASDAQ biotech stocks. See what moved their share...
March 4, 2018

5 Top NASDAQ Biotech Stocks: Tenax on top with a 51.94 Percent Increase

This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to...
February 18, 2018

5 Top NASDAQ Biotech Stocks: HTG in the Lead This Week

This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to...
February 5, 2018

Nymox Announces US NDA for Fexapotide for BPH

Nymox Pharmaceutical (NASDAQ:NYMX) announced that the Company will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment...
January 30, 2018

Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology

Nymox Pharmaceutical (NASDAQ:NYMX) reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are...